Print version ISSN 0034-8910
Rev. Saúde Pública vol.45 no.4 São Paulo Aug. 2011 Epub May 13, 2011
Sobrevida de mulheres com câncer de colo uterino diagnosticadas em um centro brasileiro
Sobrevida de mujeres con cáncer de cuello uterino diagnosticadas en un centro brasileño
Claudio Calazan do CarmoI; Ronir Raggio LuizII
IServiço de Oncologia Clínica. Hospital do Câncer II. Instituto Nacional de Câncer. Rio de Janeiro, RJ, Brasil
IIDepartamento de Bioestatística. Instituto de Ensino em Saúde. Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brasil
OBJECTIVE: To assess overall survival of women with cervical cancer and describe prognostic factors associated.
METHODS: A total of 3,341 cases of invasive cervical cancer diagnosed at the Brazilian Cancer Institute, Rio de Janeiro, southeastern Brazil, between 1999 and 2004 were selected. Clinical and pathological characteristics and follow-up data were collected. There were performed a survival analysis using Kaplan-Meier curves and a multivariate analysis through Cox model.
RESULTS: Of all cases analyzed, 68.3% had locally advanced disease at the time of diagnosis. The 5-year overall survival was 48%. After multivariate analysis, tumor staging at diagnosis was the single variable significantly associated with prognosis (p<0.001). There was seen a dose-response relationship between mortality and clinical staging, ranging from 27.8 to 749.6 per 1,000 cases-year in women stage I and IV, respectively.
CONCLUSIONS: The study showed that early detection through prevention programs is crucial to increase cervical cancer survival.
Descriptors: Uterine Cervical Neoplasms. Early Detection of Cancer. Delayed Diagnosis. Survival Analysis.
OBJETIVO: Avaliar a sobrevida global de mulheres com câncer de colo uterino e identificar fatores prognósticos relacionados.
MÉTODOS: Todos os 3.341 casos tratados no Instituto Nacional de Câncer, Rio de Janeiro, RJ, entre 1999 e 2004 foram selecionados e seus dados clínicos, anatomo-patológicos e de seguimento foram coletados. Foram utilizados a curva de Kaplan-Meier e o modelo de Cox para avaliação da sobrevida e para análise logística múltipla, respectivamente.
RESULTADOS: Dos casos estudados, 68,3% apresentavam doença localmente avançada. A sobrevida global em cinco anos foi de 48%. Após análise múltipla, o estádio clínico ao diagnóstico foi a única variável significativamente associada com o prognóstico (p<0,001). Mortalidade e o estádio clínico da doença apresentaram efeito dose-resposta, variando de 27,8 por 1.000 casos-ano a 749,6 por 1.000 casos-ano em mulheres com estádio I e IV, respectivamente.
CONCLUSÕES: Os resultados mostram que a detecção precoce por meio de programas de prevenção é fundamental para aumentar a sobrevida em câncer cervical.
Descritores: Neoplasias do Colo do Útero. Detecção Precoce de Câncer. Diagnóstico Tardio. Análise de Sobrevida.
OBJETIVO: Evaluar la sobrevida global de mujeres con cáncer de cuello uterino e identificar factores pronósticos relacionados.
MÉTODOS: Todos los 3.341 casos tratados en el Instituto Nacional de Cáncer, Rio de Janeiro, Sureste de Brasil, entre 1999 y 2004 fueron seleccionados y sus datos clínicos, anatomo-patológicos y de seguimiento fueron colectados. Se utilizaron la curva de Kaplan-meier y el modelo de Cox par evaluación de la sobrevida y para análisis logística múltiple, respectivamente.
RESULTADOS: De los casos estudiados, 68,3% presentaban enfermedad localmente avanzada. La sobrevida en cinco años fue de 48%. Posterior al análisis múltiple, el estadio clínico al diagnóstico fue la única variable significativamente asociada con el pronóstico (p<0,001). Mortalidad y el estadio clínico de la enfermedad presentaron efecto dosis-respuesta, variando de 27,8 por 1000 casos-año a 749,6 por 1000 casos-año en mujeres con estadio I y IV, respectivamente.
CONCLUSIONES: Los resultados muestran que la detección precoz por medio de programas de prevención es fundamental para aumentar la sobrevida en cáncer cervical.
Descriptores: Neoplasias del Cuello Uterino. Detección Precóz del Cáncer. Diagnóstico Tardío. Análisis de Supervivencia.
Cervical cancer is one of the most common cancers worldwide, the sixth in incidence and the third leading cause of death among women.16 Most cases (80%) are reported in developing countries in Africa, Latin America and the Caribbean, and they are relatively uncommon in Europe, Israel and the US.ª In Brazil, cervical cancer is the second leading cause of death due to cancer in women. The Brazilian Ministry of Health estimated approximately 18,430new cases in 2010b with 4,315 deaths confirmed in 2008.c
The major prognostic factor of cervical cancer is tumor staging. Tumor staging according to the International Federation of Gynecology and Obstetrics11 (FIGO) staging system is directly associated with risk of recurrence and overall survival. It assesses the primary tumor size, local extension, invasion of adjacent structures, and presence of distant lesions. However, the FIGO staging system does not assess several other factors such as age, skin color, socioeconomic condition and histopathological type of tumor, which have also been reported as prognostic factors.7,d
There is a clear relationship between the extension of disease at diagnosis (tumor staging) and disease-associated mortality. This is the basis for screening programs,10 which can effectively detect pre-invasive or early stage disease and thus reduce associated morbidity and mortality.1,11,e
The present study aimed at analyzing overall survival of women diagnosed with cervical cancer and describing prognostic factors associated.
The Brazilian National Cancer Institute (Instituto Nacional do Câncer - INCA) is a reference center for cancer prevention and control in Brazil. The INCA serves both the metropolitan area of the city of Rio de Janeiro and the rest of the state. In 2003, of 896 cases of cervical cancer diagnosed in the city of Rio de Janeiro, and 2010 cases in the state,f 597 patients were attended at the center.
A retrospective study with data obtained from INCA registries was conducted. All cases of primary cervical tumors diagnosed from 1999 to 2004 were assessed. Since 1999 the Hospital do Câncer 2 (HC2), one of the four INCA units, is a reference center for all gynecologic cancer cases.
The following variables were analyzed: age; tumor staging; histopathological type of tumor; level of education; skin color; and year of diagnosis.
Age was divided into two groups: <65 years and >65 years. Level of education was categorized as 11 or more years of schooling and less than 11 years of schooling. Skin color was categorized as white and non-white.
Cases were classified according to the FIGO staging system, stages I to IV. Histopathologically tumors were classified as: squamous cell carcinoma; adenocarcinoma; and other types.
The chi-square test was used to assess the association between tumor staging and the independent variables.
For estimating survival, all deaths during the study period were considered events; the remaining cases were censored at the last hospital visit on November 2006. Data on deaths were collected from the hospital registry and the Brazilian Mortality Database (SIM). Kaplan-Meier curves were used to analyze overall survival and the log-rank test was used for comparing survival curves.
The association between survival (dependent variable) and independent variables (staging, histopathological type of tumor, age, skin color, level of education and year of diagnosis) was assessed through Cox proportional hazards model. The proportional hazard assumption was assessed by visual inspection of the log minus log plot proportional hazards test. The case-fatality rate at each stage was calculated based on the number of deaths per person-time (incidence density).
The study was approved by INCA Ethics Commitee on Research (Process nº 52/2006).
A total of 3,341 patients with primary cervical tumors were attended at INCA during the study period, of which 68 were excluded due to missing information. The maximum follow-up time was 94.0 months (median 28.1 months).
Most patients at early stage (I) were treated with surgery as single therapy (69.5%) followed by local radiation therapy (22.5%). Only 18% of these patients were treated with radiation therapy only. This standard of care did not change along the period analyzed.
Patients with locally advanced disease (FIGO stages II and III) were treated with radiation therapy (69.8%). Combined radiation therapy and chemotherapy (weekly cisplatin) was used in 21% and it is important to note that beginning in 2004 this standard of care changed (78.5% received combined treatment).
Table 1 shows case distribution according to clinical and epidemiological characteristics by stage. Overall, missing data were minimal (age in one patient, skin color in 2, and level of education in 4 patients). Most patients were white, <65 years of age, and poorly educated. The most prevalent histological type of tumor was squamous cell carcinoma (84.5%). Locally advanced disease (stages II and III) was seen in 68.3% of the cohort. Most cases were followed-up for at least two years (80.7%), and 1,499 deaths were recorded (50.1% of cases). Deaths occurred more often in the first two years of follow-up (71.2%) and at stages II or III (84.9% of all deaths).
The chi-square analysis showed that the number of patients with 11 years of schooling or more was significantly greater at stages I and II (p<0.001), although they accounted for a small proportion of the cohort. Despite slight predominance of white patients, no statistically significant difference was seen in the distribution of cases by stage (p=0.168). Squamous cell carcinoma was most commonly seen at FIGO stage III while adenocarcinoma and adenosquamous carcinoma (plus other histological types) were more often seen at early stages (p<0.001). Year of diagnosis was not statistically significant (p=0.144) in this analysis.
Figures 1 and 2 show the Kaplan-Meier curves. The median survival for the entire cohort was 53.4 months (95% CI 47.65;59.20) and the 5-year overall survival was 48%. A significant difference was found in median survival between the two age groups studied (62.6 vs. 41.3 months, higher in the younger age group; p=0.016; Fig. 1.A). Although not significant, non-white women showed better survival compared with white ones (56.43 vs. 49.46 months; p=0.04; Fig. 1.B). As for level of education (Fig. 1.C), those with 11 years of schooling or more showed a significantly better survival (median survival has not yet been estimated for this subgroup). The median survival for those with lower education was 49.9 months, p<0.001. The histological type of tumor (Fig. 1.D) was not statistically different in terms of survival as survival curves were very similar (p=0.09). There was a clear relationship between tumor staging at diagnosis and survival (Fig. 2), i.e., greater survival rates were found at stage I (no median survival estimated), and progressively reduced at more advanced stages (65.6 months, 21.7 months and 10.4 months for stages II, III and IV, respectively; p<0.001).
In the multiple logistic analysis using Cox model only tumor staging remained statistically significant (p<0.001) (Table 2) while all other variables from the univariate analysis lost their statistical significance.
The case-fatality rate in Table 3 showed a dose-response effect between mortality and clinical stage, ranging from 27.8 to 749.6 per 1,000 cases-year in women at stages I and IV, respectively.
There are few Brazilian studies on survival of women with cervical cancer. A reference center in Paraná, southern Brazil, reported 2,396 cases (19901994) with a 5-year survival of 53.6%.g Another study conducted in São Paulo, southeastern Brazil, reported an overall 5-year survival of 66.5% representing a unexpectedly high survival rate (66.5%) for advanced cases.2
According to the American Cancer Society, the 5-year overall survival in the US is 72%.h Population-based studies have reported cancer survival rates of 62.5% in the United Kingdomi14 and 58% in Australia.1
This scenario is significantly worst in less developed regions. Although data from the 1980s in Cuba showed a 53.5% 5-year overall survival, lower rates have been reported in some cities in Asia: 46.5% in Bombay, India; 37.5% in Qidong, China; and 24.6% in Rizal, Philippines.1
Low socioeconomic condition has been associated with poor prognosis in cervical cancer.5,7,9 In our study level of education was a proxy of socioeconomic condition and there were two major findings: more educated women were a small minority (9.4%) of the cohort studied and they had a 35% reduction in the risk of death when compared with those less educated. However, this difference fell a non-significant 14% in the multiple logistic analysis. This association may be explained by the fact that more educated women usually seek health care and have more knowledge on prevention and thus their disease is detected at an earlier phase with more successful treatment. However, in the multiple logistic analysis, the clinical magnitude of the difference between level of education (HR 0.86) remained after adjustment, despite losing its statistical significance.
Data from hospital registries in Japan have showed that older age is associated with a poorer cancer survival, even after adjusting for tumor stage, and this finding is also associated with more effective screening at younger ages (<45 years).9 Another study has argued there are adverse biological factors that may cause a more aggressive course.11 However, the North American Surveillance, Epidemiology and End Results Program (SEER) did not find any significant difference after adjusting for other causes of death and life expectancy when assessing case-fatality rate due to cervical cancer in different age groups.8 In the present study, although advanced age was also associated with a poorer prognosis (HR = 1.17) in the univariate analysis, this association disappeared in the multiple logistic analysis. The high prevalence of locally advanced cancer at advanced ages may have contributed to a poorer survival in the univariate analysis.
A trend towards a worse prognosis has been reported for the histological types adenocarcinoma and adenosquamous carcinoma compared with squamous cell carcinoma,3,11 although this same trend was not seen in the multiple logistic analysis in our study. One plausible explanation may be the small number of patients with adenocarcinoma and adenosquamous carcinoma subtypes, which were most commonly seen at early stages. Another factor possibly associated is the use of more aggressive treatments in these cases (adjuvant radiation therapy), which may have contributed to increased survival. However, this is not completely understood, and the presence of residual confounding cannot be ruled out.
According to the SEER,3 white women are diagnosed at earlier stages and have a more favorable prognosis when compared with black ones (HR = 1.35). This is mainly attributed to unequal access to health care and different treatment provided.4,6 In our cohort, in the multiple logistic analysis there was no significant survival difference between white and non-white women. Given the greater number of white compared with non-white patients, it should be emphasized that, according to the 2003 National Household Survey (PNAD),j white women accounted for 61.4% of the population in the state of Rio de Janeiro, which may partially explain this difference.
Early screening and tumor staging were the main prognostic factors in the population studied. Although age and level of education had an effect in the univariate analysis, it disappeared in the multiple analysis, suggesting an independent effect of staging. This finding is consistent with the literature and confirms tumor staging as the main prognostic factor in cervical cancer.11 The prognostic significance of staging becomes more evident when the case-fatality rate at each stage is estimated.
The study limitations are related to the retrospective design and use of secondary data with no further details on treatment, such as delayed or prolonged radiation therapy and surgical procedures. Selection bias is unlikely to have affected the results because most women in the cohort were followed up for at least two years. Lead-time bias was not likely as approximately 70% of the cases were locally advanced.
This study is probably not representative of the national reality of cervical cancer given that there are wide socioeconomic differences among Brazilian macroregions (especially the North and Northeast regions). However, the results of our study are representative of the metropolitan area of Rio de Janeiro and, to a lesser extent, of the Southeast region. The 48% 5-year overall survival, compared with more developed countries like the US (72%),1 indicates a less favorable outcome consistent with that of developing countries.1
The low overall survival found at the INCA may be attributed to delayed combined treatment (radiation therapy plus chemotherapy, the standard care for locally advanced disease). With poorer prognosis at more advanced stages, it is remarkable the disproportionate high number of cases with locally advanced stages (85%, 51% and 24% at stages I, II and III, respectively), slightly lower rates than those reported in the US and UK.2,4
Further studies with longer follow-up are needed to explore improvement in specific-stage survival benefit with the recent introduction of chemotherapy plus radiation therapy as the standard care for locally advanced cancer. There is also a need for mass campaigns and prevention programs for adequate cancer management so to achieve a plateau in overall survival similar to that seen in developed countries.
1. Australian Institute of Health and Welfare. Australasian Association of Cancer Registries. Cancer survival in Australia 1992-1997: geographic categories and socioeconomic status. Canberra; 2000. [ Links ]
2. Coelho FRG, Kowalski LP, Franco IF, Contesine H, Zeferino LC . Análise de sobrevida de uma amostra de 2 mil casos de câncer tratados no Hospital A. C. Camargo de 1980 a 1987. Acta Oncol Bras. 1993;13(1/3):8-16 [ Links ]
3. Coker A, Du X, Fang S, Eggleston K. Socioeconomic status and cervical cancer survival among older women: findings from the SEER-Medicare linked data cohorts. Gynecol Oncol. 2006;102(2):278-84. [ Links ]
4. Eddy DM. Screening for cervical cancer. Ann Intern Med. 1990;113(3):214-22. [ Links ]
5. Greenwald HP, Borgatta EF, McCorkle R, Polissar N. Explaining reduced cancer mortality among disadvantaged. Milbank Q. 1996;74(2):215-38. [ Links ]
6. Kim SH, Kim SC, Choi BI, Han MC. Uterine cervical carcinoma:evaluation of pelvic lymph node metastasis with MR imaging. Radiology. 1994;190(3):80711. [ Links ]
7. Newmann SJ, Garner EQ. Social inequities along the cervical cancer continuum: a structured review. Cancer Causes Control. 2005;16(1):63-70. DOI:10.1007/s10552-004-1290-y [ Links ]
8. Parkin DM, Pisani P, Ferlay J. Global Cancer Statistics. CA Cancer J Clin. 1999;49(1):33-64. DOI:10.3322/canjclin.49.1.33 [ Links ]
9. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer; 2002. (Scientific Publications, 155) [ Links ]
10. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364(9430):249-58. DOI:10.1016/S0140-6736(04)16674-9 [ Links ]
11. Shepperd JH. Staging announcement: FIGO staging of gynecologic cancers; cervical and vulva. Int J Gynecol Cancer. 1995;5:319-25. [ Links ]
Claudio Calazan do Carmo
Instituto Nacional de Câncer
R. Equador 831 - Santo Cristo
22220-040 Rio de Janeiro, RJ, Brasil
a Ferlay J, Parkin DM, Pisani P. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: International Agency for Research on Cancer; 2004.
b Ministério da Saúde, Secretaria Nacional de Assistência a Saúde, Instituto Nacional de Câncer. Estimativa da incidência e mortalidade por câncer no Brasil. Rio de Janeiro; 2007.
c Ministério da Saúde. DATASUS. 1. Sistema de Informação de Mortalidade (SIM). Indicadores e Dados Básicos - Brasil 2008. IDB-2008. Brasília; 2009.
d American Joint Committee on Cancer. Manual for staging of cancer: cervix uteri. 3. ed. Philadelphia: Lippincott; 1998.
e International Agency for Research on Cancer. IARC confirms efficacy of cervix cancer screening for women 25-65 in reducing mortality. Lyon; 2004. [cited 2011 Mar 15]Available from: http://www.iarc.fr/en/media-centre/pr/2004/pr151.html
f Ministério da Saúde. DATASUS. 1. Sistema de Informação de Mortalidade (SIM). Indicadores e Dados Básicos - Brasil - 2005. IDB-2005. Brasília; 2006. [cited 2011 Mar 15] Available from: http://tabnet.datasus.gov.br/cgi/idb2005/matriz.htm
g Liga Paranaense de Combate ao Câncer. Relatório Epidemiológico: RHC 2000 a 2004. Curitiba: Hospital Erasto Gaertner; 2007.
h American Cancer Society. Cancer facts and figures. Atlanta; 1999.
i London Research Institute. Cancer Research United Kingdom. Cancer Statistics in the United Kingdom. London; 2009. [cited Mar 19]Available from: http://info.cancerresearchuk.org/cancerstats/types/cervix/survival
j Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional por Amostra de Domicílios 2003. Rio de Janeiro; 2003 [citado 2011 abr 9]. Disponível em: http://www.ibge.gov.br/home/estatistica/populacao/trabalhoerendimento/pnad2008/ default.shtm